ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Denver, Colorado.
Science
ARCA is currently developing bucindolol for the treatment of heart failure. ARCA anticipates submitting an application with the FDA for approval of bucindolol in 2008. Bucindolol will have market exclusivity through 2024.
